Celgene Co. (CELG) Holdings Trimmed by Comerica Bank

Comerica Bank lowered its stake in shares of Celgene Co. (NASDAQ:CELG) by 1.6% during the third quarter, HoldingsChannel.com reports. The firm owned 250,281 shares of the biopharmaceutical company’s stock after selling 4,087 shares during the period. Comerica Bank’s holdings in Celgene were worth $25,271,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Xact Kapitalforvaltning AB raised its stake in shares of Celgene by 7.0% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 183,759 shares of the biopharmaceutical company’s stock valued at $23,865,000 after acquiring an additional 12,034 shares during the period. Bremer Trust National Association raised its stake in shares of Celgene by 18.4% in the 2nd quarter. Bremer Trust National Association now owns 22,552 shares of the biopharmaceutical company’s stock valued at $2,929,000 after acquiring an additional 3,509 shares during the period. Boltwood Capital Management raised its stake in shares of Celgene by 3.3% in the 2nd quarter. Boltwood Capital Management now owns 6,995 shares of the biopharmaceutical company’s stock valued at $908,000 after acquiring an additional 225 shares during the period. Trust Co raised its stake in shares of Celgene by 3.5% in the 1st quarter. Trust Co now owns 17,741 shares of the biopharmaceutical company’s stock valued at $2,208,000 after acquiring an additional 606 shares during the period. Finally, Burns J W & Co. Inc. NY raised its stake in shares of Celgene by 3.6% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 44,688 shares of the biopharmaceutical company’s stock valued at $5,804,000 after acquiring an additional 1,554 shares during the period. 79.74% of the stock is currently owned by institutional investors.

Celgene Co. (CELG) opened at $106.00 on Friday. Celgene Co. has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The company has a market cap of $83,460.00, a PE ratio of 25.00, a PEG ratio of 0.68 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the business posted $1.58 EPS. The company’s quarterly revenue was up 10.2% on a year-over-year basis. analysts anticipate that Celgene Co. will post 6.68 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus set a $130.00 target price on shares of Celgene and gave the company a “buy” rating in a research note on Monday, January 8th. SunTrust Banks set a $127.00 target price on shares of Celgene and gave the company a “buy” rating in a research note on Monday, January 8th. Guggenheim reissued a “buy” rating and issued a $147.00 target price on shares of Celgene in a research note on Wednesday. Oppenheimer set a $166.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Monday, January 8th. Finally, Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a research note on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have given a buy rating to the company. Celgene presently has a consensus rating of “Buy” and a consensus target price of $131.18.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.com-unik.info/2018/01/13/celgene-co-celg-holdings-trimmed-by-comerica-bank.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit